{"id":497755,"date":"2024-01-26T19:11:26","date_gmt":"2024-01-27T00:11:26","guid":{"rendered":"https:\/\/platohealth.ai\/emas-chmp-confirms-non-renewal-of-translarna-denies-new-medicines-nezglyal-and-syfovre\/"},"modified":"2024-01-27T15:44:13","modified_gmt":"2024-01-27T20:44:13","slug":"emas-chmp-confirms-non-renewal-of-translarna-denies-new-medicines-nezglyal-and-syfovre","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/emas-chmp-confirms-non-renewal-of-translarna-denies-new-medicines-nezglyal-and-syfovre\/","title":{"rendered":"EMA\u2019s CHMP confirms non-renewal of Translarna, denies new medicines\u00a0Nezglyal and Syfovre","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

DATA GRAPHICS | Data Byte<\/p>\n

\n
\n
\n

On the positive side of the ledger, BMS\u2019s CAR T therapy Abecma headed for a line extension<\/h2>\n

\n By Gunjan Ohri, Data Content Analyst<\/span><\/span>\n<\/p>\n

January 27, 2024 12:11 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Negative opinions and non-renewals headlined this month\u2019s recommendations from EMA\u2019s CHMP.<\/p>\n

After re-examination. EMA\u2019s CHMP has again concluded that the effectiveness of Duchenne muscular dystrophy therapy Translarna ataluren from PTC Therapeutics Inc.<\/a> (NASDAQ:PTCT) cannot be confirmed from Phase III study 041, which was required to convert the drug\u2019s conditional authorization, granted in 2014, to full approval. The agency noted that the mechanism of action could not be confirmed from additional studies showing a small effect on dystrophin protein production. …<\/p>\n